Transfer of the Oral Gonadotropin-Releasing Hormone Receptor Antagonist Relugolix Into Breast Milk of Healthy Lactating Women
- PMID: 39887952
- PMCID: PMC11781947
- DOI: 10.1002/prp2.70067
Transfer of the Oral Gonadotropin-Releasing Hormone Receptor Antagonist Relugolix Into Breast Milk of Healthy Lactating Women
Abstract
Relugolix is an oral gonadotropin-releasing hormone receptor antagonist that suppresses sex steroid hormones and is approved as monotherapy for prostate cancer and as a fixed-dose combination with estradiol/norethindrone for the treatment of endometriosis and uterine fibroids. The aim of this postmarketing study was to determine the pharmacokinetics and quantify the amount of relugolix excreted into breast milk of healthy lactating women. Following a single, oral dose of 40 mg relugolix, breast milk was sampled over 120 h. Pharmacokinetic parameters were determined, including the cumulative amount of relugolix excreted into breast milk to derive the total infant dose. The safety and tolerability of relugolix were also assessed. Eight healthy lactating women were enrolled and completed the study per protocol. Relugolix was safe and well tolerated based on adverse events and other safety data. It was excreted into breast milk with a median time to peak concentration (tmax) of 5.81 h and a geometric mean peak concentration (Cmax) of 15.7 ng/mL, similar to corresponding plasma data from previous clinical studies. The mean cumulative amount of relugolix excreted was 0.0051 mg over 24 h and 0.0067 mg over 120 h, corresponding to 0.0128% and 0.0167% of the maternal dose, respectively. The body weight-adjusted relative daily infant dose of approximately 0.25% suggests a 400-fold lower newborn than maternal relugolix exposure. Relevant effects of relugolix on the breastfed child appear unlikely given its limited excretion into breast milk of lactating women but cannot be fully excluded in the absence of infant safety data.
Keywords: breast milk; endometriosis; gonadotropin; lactation; pharmacokinetics; relugolix; uterine fibroids.
© 2025 The Author(s). Pharmacology Research & Perspectives published by John Wiley & Sons Ltd, British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics.
Conflict of interest statement
Y.‐L.C., K.Y., and M.U. are employees of Sumitomo Pharma. S.L. is a former employee of Sumitomo Pharma. D.B.B. served as the principal investigator.
Figures


Similar articles
-
Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, reduces endometriosis-associated pain in a dose-response manner: a randomized, double-blind, placebo-controlled study.Fertil Steril. 2021 Feb;115(2):397-405. doi: 10.1016/j.fertnstert.2020.07.055. Epub 2020 Sep 7. Fertil Steril. 2021. PMID: 32912633 Clinical Trial.
-
Transfer of the Dual Orexin Receptor Antagonist Daridorexant into Breast Milk of Healthy Lactating Women.J Clin Pharmacol. 2024 Oct;64(10):1278-1287. doi: 10.1002/jcph.2455. Epub 2024 May 12. J Clin Pharmacol. 2024. PMID: 38736033 Clinical Trial.
-
Relugolix/Estradiol/Norethisterone Acetate: A Review in Endometriosis-Associated Pain.Drugs. 2024 Apr;84(4):449-457. doi: 10.1007/s40265-024-02018-3. Epub 2024 Apr 9. Drugs. 2024. PMID: 38592603 Free PMC article. Review.
-
Relugolix, a novel oral gonadotropin-releasing hormone antagonist, in the treatment of pain symptoms associated with uterine fibroids: a randomized, placebo-controlled, phase 3 study in Japanese women.Fertil Steril. 2019 Nov;112(5):922-929.e2. doi: 10.1016/j.fertnstert.2019.07.013. Epub 2019 Oct 6. Fertil Steril. 2019. PMID: 31594635 Clinical Trial.
-
Relugolix/Estradiol/Norethisterone (Norethindrone) Acetate: A Review in Symptomatic Uterine Fibroids.Drugs. 2022 Oct;82(15):1549-1556. doi: 10.1007/s40265-022-01790-4. Epub 2022 Nov 4. Drugs. 2022. PMID: 36331779 Free PMC article. Review.
References
-
- Stewart E. A., Lukes A. S., Venturella R., et al., “Relugolix Combination Therapy for Uterine Leiomyoma‐Associated Pain in the LIBERTY Randomized Trials,” Obstetrics and Gynecology 139, no. 6 (2022): 1070–1081. - PubMed
-
- US Food and Drug Administration—Center for Drug Evaluation Research , “Myfembree: Clinical Pharmacology and Biopharmaceutics Review(s),” 2021, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214846Orig1s000C....
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources